StarMat Technologies
Developers of gene therapy treatments are actively searching for non-viral delivery technologies for greater tolerability, re-dose potential and effectiveness. Having developed a family of novel polyamino acid materials, StarMAT aims to revolutionise the formulation and delivery of mRNA gene therapies by exploring the inherent biocompatibility, power and flexibility to configure polyaminoacid chemistry for more targeted, effective, safer delivery of genetic medicines which can be re-dosed.
There is a renewed interest in mRNA therapeutics and increasing demand for better targeted and stable delivery systems. Deactivated viruses, the traditional delivery vehicle for therapeutic genes, cannot be used for up to 60% of patients due to immunogenic response and is not recommended for re-dose. Despite recent progress with advanced gene delivery technologies, significant development issues with clinical translation remain. StarMat has potential for safe, efficient targeted gene therapy delivery with low immunogenicity risk and high re-dose potential.
StarMAT’s technology is based around a versatile and tuneable poly amino acid platform to optimise for payload, target and release profile. It’s a scalable CMC and controlled polyplex formulation using microfluidics. It has high loading and excellent stability under ambient conditions and its versatility has been demonstrated for nucleic acid cargos (siRNA, mRNA, pDNA), proteins, small molecule.
Promoters
- Dr Sarinj Fattah, Academic Lead
- Mike Mulcahy, Business Lead
Current status
- Significant in-vitro data and preliminary in-vivo data available
- Product development plan includes accelerated regulatory strategy for rare disease therapeutic for US and Europe
- Patent application filed
- Completing EI Commercialisation Fund to further develop the technology
Next steps
- Seeking collaborative research partnerships with industry customers
- Spin-out in 2025
